swissmedic

CERTIFICATE OF GMP COMPLIANCE

We certify herewith

that the company **Future Health Biobank SA, Route de Pra-de-Plan 3, 1618 Châtel-St-Denis, Switzerland,** has been duly authorized to manufacture and distribute transplant products, the manufacturing licence includes the following product categories:

- not ready to use cell therapy products for autologous use or allogenic use
- ready to use cell therapy products for autologous use or allogenic use

that the finished transplant products put on the market in Switzerland by the company are subject to appraisal and authorisation by our agency;

that the company is keeping the required level for good practices in the manufacture of pharmaceutical products according to the Swiss regulations in force. These regulations are in accordance with the requirements for good practices in the manufacture and quality control of the Pharmaceutical Inspection Convention /Co-operation Scheme (PIC/S) and the Directives of the European Commission;

that the manufacturing plant of the company is subject to official periodic inspections; the last regular inspection was conducted on **24/25 March 2015**;

that the requirements regarding manufacture and quality control for pharmaceutical products for export are according to PIC's and to European Commission Guidelines and are identical to those applicable to products sold in Switzerland.

Berne, 11 May 2016

No. 16-0996

Swissmedic, Swiss Agency for Therapeutic Products

Dr. Julia Djonova